Edition:
United States

Omeros Corp (OMER.A)

OMER.A on American Stock Exchange

18.76USD
22 Nov 2017
Change (% chg)

$0.51 (+2.79%)
Prev Close
$18.25
Open
--
Day's High
$18.76
Day's Low
$18.76
Volume
0
Avg. Vol
--
52-wk High
$24.91
52-wk Low
$13.21

Latest Key Developments (Source: Significant Developments)

Omeros reports Q1 revenue $12.3 million
Wednesday, 10 May 2017 04:02pm EDT 

May 10 (Reuters) - Omeros Corp :Omeros Corporation reports first quarter 2017 financial results.Q1 loss per share $0.34.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Q1 revenue $12.3 million versus I/B/E/S view $13.3 million.  Full Article

Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
Thursday, 30 Mar 2017 07:00am EDT 

Omeros Corp : Omeros reports more positive data in OMS721 phase 2 trial in renal diseases . Phase 3 program slated for this year . Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed . Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year .New data corroborate and expand on trial results reported in Q4 of 2016.  Full Article

Omeros to present results from dose-ranging stage of OMS721 Clinical Trial
Monday, 27 Mar 2017 07:00am EDT 

Omeros Corp : Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros corp - mean change from baseline in platelet count was statistically significant as measured by area under curve .Omeros- renal replacement therapy able to be discontinued in 1 patient during oms721 treatment, renal function remained stable following completion of treatment.  Full Article

Omeros reports additional positive results from OMS721 Phase 2 trial
Wednesday, 1 Mar 2017 07:00am EST 

Omeros Corp : Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy . Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment . Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment . Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721 .Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment..  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 10:49am EDT 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 09:27am EDT 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

Omeros enters debt financing transaction for $20 mln in additional funds
Tuesday, 17 May 2016 07:00am EDT 

Omeros Corp : Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash . Will issue warrants to lenders, exercisable for 7 years for up to 100,602 shares of common stock at an exercise price per share of $9.94 . Expects funding will occur on may 18, 2016. .Omeros announces debt financing transaction for $20 million in additional funds.  Full Article

Omeros Corporation reports Q1 loss per share $0.54
Tuesday, 10 May 2016 07:29am EDT 

Omeros Corp : Omeros corporation reports first quarter 2016 financial results . Q1 loss per share $0.54 . Q1 revenue $7.4 million versus I/B/E/S view $8.8 million . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S ."continue to expect that we will reach cash-flow positive status later this year, fully funding our pipeline".  Full Article

Omeros Corp announces exclusive Middle East distribution agreement
Tuesday, 10 May 2016 07:00am EDT 

Omeros Corporation : Omeros Corporation announces exclusive middle east distribution agreement for omidria .Distribution agreement for sale of omidria in Saudi Arabia, UAE and other countries in Middle East with Itrom Trading Drug Store.  Full Article

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results